Meeting
2023 ASCO Genitourinary Cancers Symposium
Phase 1/2 study of EPI-7386 in combination with enzalutamide (enz) compared with enz alone in subjects with metastatic castration-resistant prostate cancer (mCRPC).
Authors
Andrew Leonard Laccetti
Memorial Sloan Kettering Cancer Center, New York, NY
Andrew Leonard Laccetti , Gurkamal S. Chatta , Nicholas Iannotti , Christos Kyriakopoulos , Karen Villaluna , Ronan Le Moigne , Alessandra Cesano
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05075577
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 179)
DOI
10.1200/JCO.2023.41.6_suppl.179
Abstract #
179
Poster Bd #
F16
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Phase 1/2 trial of oral EPI-7386 (masofaniten) in combination with enzalutamide (Enz) compared to Enz alone in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase 1 (P1) results and phase 2 (P2) design.
First Author: Christos Kyriakopoulos
Poster
2023 ASCO Genitourinary Cancers Symposium
Oral EPI-7386 in patients with metastatic castration-resistant prostate cancer.
First Author: Russell Kent Pachynski
Poster
2023 ASCO Genitourinary Cancers Symposium
Phase Ib trial of enzalutamide (Enza) with venetoclax (Ven) in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Stuthi Perimbeti
First Author: Johann S. De Bono